

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### STA Lenalidomide plus dexamethasone for previously untreated multiple myeloma

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final appraisal determination

(when no ACD was issued)

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

A potential equality issue was identified during the draft scope consultation:

Access to treatment: people with multiple myeloma attend specialist treatment units for injectable treatment. These patients are often less mobile or live a long distance from their treatment centre meaning they are less likely to receive these treatments.

It was agreed that the benefits of different modes of administration will be taken into account in the appraisal.

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No issues raised.

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No issues raised.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No. Lenalidomide is recommended in line with the company value proposition.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No. Lenalidomide is recommended in line with the company value proposition.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/a

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

It was considered whether lenalidomide was innovative because it is taken orally, whereas people have to attend specialist treatment units to have subcutaneous or intravenous bortezomib (addressing the potential equality issue under point 1). Considerations described in section 3.19 of the Final Appraisal Document.

**Approved by Associate Director (name):** Elisabeth George

**Date:** 03/04/2018